Eli Lilly and Co

Prescription weight loss drugs like Ozempic and Wegovy are in high demand, leading to shortages and people turning to compounded drugs. Jean Readdy, a retired teacher, switched to compounded tirzepatide due to cost and availability issues. Compounded drugs, not FDA-reviewed, come with risks and potential dosing errors, yet many telehealth companies market them as 'generic' versions. The FDA may restrict compounded drug manufacturing as shortages ease.

The global Personalized Precision Medicine Market report offers detailed segmentation and strategic guidance, covering manufacturers, regions, product categories, and applications. Key insights include market evolution, current conditions, future projections, and analysis of key players like Agilent Technologies, Biogen, Johnson & Johnson, and Novartis. The report aids stakeholders in navigating market dynamics and capitalizing on opportunities.

Alec Stranahan from Bank of America Securities maintains a Buy rating on Eli Lilly & Co (LLY) with a $1,150.00 price target, citing Lilly's competitive edge in obesity treatment, favorable safety profile of orforglipron, and efforts to resolve supply shortages. Corporate insider sentiment is negative, with increased insider selling.

EMA approves Novo Nordisk's Wegovy for obesity-related heart failure, expanding its therapeutic uses beyond weight loss. Clinical trial data showed weight loss and improved health status in patients after one year. Novo Nordisk plans to resubmit data to the FDA next year.

The weight-loss drug market is booming, with Viking Therapeutics emerging as a contender. VKTX stock is attracting billionaire investors and analysts predict significant gains. Viking's VK2735, a dual GLP-1/GIP agonist, is set to skip to Phase 3, challenging industry giants like Eli Lilly and Novo Nordisk.

FDA approves Eli Lilly’s Ebglyss for eczema, Novartis’ Kisqali for early breast cancer, Merck’s Keytruda for malignant pleural mesothelioma, J&J’s Rybrevant for advanced lung cancer, and AstraZeneca’s Fasenra for eosinophilic granulomatosis with polyangiitis.

A UM Miller School research team won a $100,000 grant for a novel therapeutic strategy targeting brain disorders like Alzheimer’s and Dravet syndrome, using a single molecule to target multiple genes.

FDA clears Eversense 365, the first 1-year CGM for diabetes. Approves lebrikizumab-lbkz for moderate-to-severe atopic dermatitis, benralizumab for eosinophilic granulomatosis with polyangiitis, and ribociclib plus aromatase inhibitor for HR+/HER2- early breast cancer.

Two new Alzheimer's drugs, lecanemab and donanemab, spark controversy over their effectiveness and cost, with some experts seeing them as a breakthrough and others as a disappointment. The drugs reduce cognitive decline by about 30% but come with risks and high costs, leading to differing national approvals. Critics argue the benefits are minimal, while supporters believe they offer crucial extra months of autonomy.